Research ExplorerPublicationsRisk-adjusted therapy of acute lymphoblastic leukemia can de...

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival

Standard

Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival : treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. / Möricke, Anja; Reiter, Alfred; Zimmermann, Martin; Gadner, Helmut; Stanulla, Martin; Dördelmann, Michael; Löning, Lutz; Beier, Rita; Ludwig, Wolf-Dieter; Ratei, Richard; Harbott, Jochen; Boos, Joachim; Mann, Georg; Niggli, Felix; Feldges, Andreas; Henze, Günter; Welte, Karl; Beck, Jörn-Dirk; Klingebiel, Thomas; Niemeyer, Charlotte; Zintl, Felix; Bode, Udo; Urban, Christian; Wehinger, Helmut; Niethammer, Dietrich; Riehm, Hansjörg; Schrappe, Martin; German-Austrian-Swiss ALL-BFM Study Group.

In: BLOOD, Vol. 111, No. 9, 01.05.2008, p. 4477-89.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Möricke, A, Reiter, A, Zimmermann, M, Gadner, H, Stanulla, M, Dördelmann, M, Löning, L, Beier, R, Ludwig, W-D, Ratei, R, Harbott, J, Boos, J, Mann, G, Niggli, F, Feldges, A, Henze, G, Welte, K, Beck, J-D, Klingebiel, T, Niemeyer, C, Zintl, F, Bode, U, Urban, C, Wehinger, H, Niethammer, D, Riehm, H, Schrappe, M & German-Austrian-Swiss ALL-BFM Study Group 2008, 'Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95', BLOOD, vol. 111, no. 9, pp. 4477-89. https://doi.org/10.1182/blood-2007-09-112920

APA

Möricke, A., Reiter, A., Zimmermann, M., Gadner, H., Stanulla, M., Dördelmann, M., Löning, L., Beier, R., Ludwig, W-D., Ratei, R., Harbott, J., Boos, J., Mann, G., Niggli, F., Feldges, A., Henze, G., Welte, K., Beck, J-D., Klingebiel, T., ... German-Austrian-Swiss ALL-BFM Study Group (2008). Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. BLOOD, 111(9), 4477-89. https://doi.org/10.1182/blood-2007-09-112920

Vancouver

Möricke A, Reiter A, Zimmermann M, Gadner H, Stanulla M, Dördelmann M et al. Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95. BLOOD. 2008 May 1;111(9):4477-89. https://doi.org/10.1182/blood-2007-09-112920

Bibtex

@article{e7334e3416ba483aaac3bc9e711bbd34,
title = "Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95",
abstract = "The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.",
keywords = "Adolescent, Antineoplastic Combined Chemotherapy Protocols, Central Nervous System Neoplasms, Child, Child, Preschool, Cranial Irradiation, Cytarabine, Female, Humans, Infant, Male, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Risk Assessment, Secondary Prevention, Survival Analysis",
author = "Anja M{\"o}ricke and Alfred Reiter and Martin Zimmermann and Helmut Gadner and Martin Stanulla and Michael D{\"o}rdelmann and Lutz L{\"o}ning and Rita Beier and Wolf-Dieter Ludwig and Richard Ratei and Jochen Harbott and Joachim Boos and Georg Mann and Felix Niggli and Andreas Feldges and G{\"u}nter Henze and Karl Welte and J{\"o}rn-Dirk Beck and Thomas Klingebiel and Charlotte Niemeyer and Felix Zintl and Udo Bode and Christian Urban and Helmut Wehinger and Dietrich Niethammer and Hansj{\"o}rg Riehm and Martin Schrappe and {German-Austrian-Swiss ALL-BFM Study Group}",
year = "2008",
month = may,
day = "1",
doi = "10.1182/blood-2007-09-112920",
language = "English",
volume = "111",
pages = "4477--89",
journal = "BLOOD",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "9",

}

RIS

TY - JOUR

T1 - Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival

T2 - treatment results of 2169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95

AU - Möricke, Anja

AU - Reiter, Alfred

AU - Zimmermann, Martin

AU - Gadner, Helmut

AU - Stanulla, Martin

AU - Dördelmann, Michael

AU - Löning, Lutz

AU - Beier, Rita

AU - Ludwig, Wolf-Dieter

AU - Ratei, Richard

AU - Harbott, Jochen

AU - Boos, Joachim

AU - Mann, Georg

AU - Niggli, Felix

AU - Feldges, Andreas

AU - Henze, Günter

AU - Welte, Karl

AU - Beck, Jörn-Dirk

AU - Klingebiel, Thomas

AU - Niemeyer, Charlotte

AU - Zintl, Felix

AU - Bode, Udo

AU - Urban, Christian

AU - Wehinger, Helmut

AU - Niethammer, Dietrich

AU - Riehm, Hansjörg

AU - Schrappe, Martin

AU - German-Austrian-Swiss ALL-BFM Study Group

PY - 2008/5/1

Y1 - 2008/5/1

N2 - The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.

AB - The trial ALL-BFM 95 for treatment of childhood acute lymphoblastic leukemia was designed to reduce acute and long-term toxicity in selected patient groups with favorable prognosis and to improve outcome in poor-risk groups by treatment intensification. These aims were pursued through a stratification strategy using white blood cell count, age, immunophenotype, treatment response, and unfavorable genetic aberrations providing an excellent discrimination of risk groups. Estimated 6-year event-free survival (6y-pEFS) for all 2169 patients was 79.6% (+/- 0.9%). The large standard-risk (SR) group (35% of patients) achieved an excellent 6y-EFS of 89.5% (+/- 1.1%) despite significant reduction of anthracyclines. In the medium-risk (MR) group (53% of patients), 6y-pEFS was 79.7% (+/- 1.2%); no improvement was accomplished by the randomized use of additional intermediate-dose cytarabine after consolidation. Omission of preventive cranial irradiation in non-T-ALL MR patients was possible without significant reduction of EFS, although the incidence of central nervous system relapses increased. In the high-risk (HR) group (12% of patients), intensification of consolidation/reinduction treatment led to considerable improvement over the previous ALL-BFM trials yielding a 6y-pEFS of 49.2% (+/- 3.2%). Compared without previous trial ALL-BFM 90, consistently favorable results in non-HR patients were achieved with significant treatment reduction in the majority of these patients.

KW - Adolescent

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Central Nervous System Neoplasms

KW - Child

KW - Child, Preschool

KW - Cranial Irradiation

KW - Cytarabine

KW - Female

KW - Humans

KW - Infant

KW - Male

KW - Precursor Cell Lymphoblastic Leukemia-Lymphoma

KW - Risk Assessment

KW - Secondary Prevention

KW - Survival Analysis

U2 - 10.1182/blood-2007-09-112920

DO - 10.1182/blood-2007-09-112920

M3 - SCORING: Journal article

C2 - 18285545

VL - 111

SP - 4477

EP - 4489

JO - BLOOD

JF - BLOOD

SN - 0006-4971

IS - 9

ER -